Syndax Pharmaceuticals has entered a non-exclusive agreement with AstraZeneca to start a Phase Ib trial of durvalumab in combination with SNDX-6352 in the treatment of various solid tumours.

The trial is expected to begin in the first half of this year with the aim to establish the safety and recommended dose regimen of SNDX-6352 and durvalumab combination.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Findings of the trial are anticipated to allow both companies to sponsor, design and initiate subsequent Phase II studies to explore the safety and efficacy of the combination across a number of defined tumour types.

Syndax CEO Briggs Morrison said: “It is thought that tumour-associated macrophages (TAMs) mediate immunosuppressive effects in the tumour microenvironment, which may limit the benefit of some immunotherapies, including those targeting PD-L1.

“SNDX-6352 has been shown to reduce the activity of TAMs, which we hope will translate to improved patient outcomes.

“SNDX-6352 has been shown to reduce the activity of TAMs, which we hope will translate to improved patient outcomes.”

“This collaboration seeks to determine whether SNDX-6352 combined with durvalumab could offer patients a greater benefit than either therapy alone, in specific clinical settings.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Durvalumab is developed by AstraZeneca as a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1).

Syndax’s SNDX-6352 is a monoclonal antibody inhibitor of colony-stimulating factor 1 receptor (CSF1R).

According to Syndax, inhibition of signalling through the CSF-1 receptor has been found to lead to the depletion of tumour associated macrophages (TAMS) cells, which are immuno-suppressive and found in the tumour microenvironment that can inhibit the ability of tumour infiltrating lymphocytes to attack and kill cells.

SNDX-6352 is currently being investigated in a Phase ll multiple ascending dose clinical trial.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact